Metastatic Pancreatic Carcinoma Clinical Trial
This study is being done to determine whether it is possible to use an investigational
vaccine that consists of dendritic cells in patients with pancreas cancer. Dendritic cells
are immune cells that are obtained from your blood that are important in the body's immune
response to foreign substances. The vaccine would be injected directly into a tumor that has
spread to the liver after a short course of radiation therapy has been given to that tumor.
The study will try to determine if this treatment would be safe and effective in treating
this cancer.
This is a phase 1 pilot study of this treatment. Phase 1 trials test the best way to give a
treatment where little is known about its possible risks or benefits. Phase 2 studies then
test the possible benefits of a treatment and may show the specific situations where they
are seen. Promising treatments are then tested in Phase 3 trials which compare the new
treatment to standard treatment in a larger group of patients. Phase 4 trials are those
conducted on a treatment after it has been approved for general use outside of research. A
pilot study tests a treatment in a small number of patients to learn if and how the
treatment could be tested in a larger group. Pilot studies can be performed at any phase but
are commonly performed in the earliest phases of research on a treatment.
n/a
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00137761 -
Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT04673448 -
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 1 | |
| Recruiting |
NCT05642962 -
Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05053971 -
Testing A New Anti-cancer Drug Combination, Entinostat and ZEN003694, for Advanced and Refractory Solid Tumors and Lymphomas
|
Phase 1/Phase 2 | |
| Terminated |
NCT04390243 -
Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients With a Somatic BRAF V600E Mutation
|
Phase 2 | |
| Recruiting |
NCT05038254 -
Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events
|
N/A | |
| Recruiting |
NCT05733000 -
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
|
Phase 2 | |
| Terminated |
NCT03818165 -
Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases
|
Phase 1 | |
| Active, not recruiting |
NCT02595931 -
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
| Recruiting |
NCT04858009 -
Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis
|
Phase 2 | |
| Recruiting |
NCT05759923 -
First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours
|
Phase 1 | |
| Recruiting |
NCT03825289 -
Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT03033225 -
Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study
|
Phase 2 | |
| Recruiting |
NCT04550494 -
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
|
Phase 2 | |
| Completed |
NCT00480584 -
A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
|
Phase 1 |